share_log

Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $3

Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $3

Benchmark维持对ImmunoPrecise Antibodies的投机性买入评级,将价格目标下调至3美元
Benzinga ·  08/14 12:32  · 评级/大行评级

Benchmark analyst Robert Wasserman maintains ImmunoPrecise Antibodies (NASDAQ:IPA) with a Speculative Buy and lowers the price target from $5 to $3.

基准分析师罗伯特·瓦斯曼维持对ImmunoPrecise Antibodies(纳斯达克: IPA)的投机买入评级,并将价格目标从$5降至$3。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发